Acetylation of nuclear receptors in cellular growth and apoptosis

Biochemical Pharmacology

Volumn 68, Issue 6, 2004, Pages 1199-1208

  Fu, Maofu ^a   Wang, Chenguang ^a   Zhang, Xueping ^a   Pestell, Richard G ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

androgen receptor; AR; ER ; estrogen receptor ; HATs; HDACs; histone acetyltransferases; histone deacetylases; N CoR; NR; nuclear receptor; peroxisome proliferator activated receptor ; PPAR ; SRC 1; steroid receptor coactivator 1

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; HISTONE ACETYLTRANSFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ACETYLATION; APOPTOSIS; BIOMECHANICS; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONFERENCE PAPER; DNA REPAIR; GENE CONTROL; GENE TARGETING; GENE TRANSLOCATION; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

ACETYLATION; ACETYLTRANSFERASES; ANIMALS; APOPTOSIS; CELL DIVISION; CELLS, CULTURED; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 4143114765     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.05.037     Document Type: Conference Paper

References (108)

1. Strahl B.D., Allis C.D. The language of covalent histone modifications. Nature. 403(6765):2000;41-45
2. Jenuwein T., Allis C.D. Translating the histone code. Science. 293(5532):2001;1074-1080
3. Berger S.L. Histone modifications in transcriptional regulation. Curr. Opin. Genet. Dev. 12(2):2002;142-148
4. Cocklin R.R., Wang M. Identification of methylation and acetylation sites on mouse histone H3 using matrix-assisted laser desorption/ionization time-of-flight and nanoelectrospray ionization tandem mass spectrometry. J. Protein Chem. 22(4):2003;327-334
5. Kanno T., Kanno Y., Siegel R.M., Jang M.K., Lenardo M.J., Ozato K. Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol. Cell. 13(1):2004;33-43
6. Carrozza M.J., Utley R.T., Workman J.L., Cote J. The diverse functions of histone acetyltransferase complexes. Trends Genet. 19(6):2003;321-329
7. Grant P.A., Berger S.L. Histone acetyltransferase complexes. Semin. Cell Dev. Biol. 10(2):1999;169-177
8. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370(Pt 3):2003;737-749
9. Thiagalingam S., Cheng K.H., Lee H.J., Mineva N., Thiagalingam A., Ponte J.F. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci. 983:2003;84-100
10. Gao L., Cueto M.A., Asselbergs F., Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J. Biol. Chem. 277(28):2002;25748-25755
11. Chiarugi V., Cinelli M., Magnelli L. Acetylation and phosphorylation of the carboxy-terminal domain of p53: regulative significance. Oncol. Res. 10(2):1998;55-57
12. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 90(4):1997;595-606
13. Boyes J., Byfield P., Nakatani Y., Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature. 396(6711):1998;594-598
14. Hayakawa F., Towatari M., Ozawa Y., Tomita A., Privalsky M.L., Saito H. Functional regulation of GATA-2 by acetylation. J Leukoc Biol. 75(3):2004;529-540
15. Yamagata T., Mitani K., Oda H., Suzuki T., Honda H., Asai T., et al. Acetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organs. EMBO J. 19(17):2000;4676-4687
16. Zhang W., Bieker J.J. Acetylation and modulation of erythroid Kruppel-like factor (EKLF) activity by interaction with histone acetyltransferases. Proc. Natl. Acad. Sci. U.S.A. 95(17):1998;9855-9860
17. Yamaguchi Y., Imai Y., Izutsu K., Asai T., Ichikawa M., Yamamoto G., et al. AML1 is functionally regulated through p300-mediated acetylation on specific lysine residues. J. Biol. Chem. 279(15):2004;15630-15638
18. Fu M., Wang C., Reutens A.T., Wang J., Angeletti R.H., Siconolfi-Baez L., et al. p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J. Biol. Chem. 275(27):2000;20853-20860
19. Fu M., Wang C., Wang J., Zhang X., Sakamaki T., Yeung Y.G., et al. Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol. Cell Biol. 22(10):2002;3373-3388
20. Gaughan L., Logan I.R., Cook S., Neal D.E., Robson C.N. Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J. Biol. Chem. 277(29):2002;25904-25913
21. Fu M., Rao M., Wang C., Sakamaki T., Wang J., Di Vizio D., et al. Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol. Cell Biol. 23(23):2003;8563-8575
22. Wang C., Fu M., Angeletti R.H., Siconolfi-Baez L., Reutens A.T., Albanese C., et al. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J. Biol. Chem. 276(21):2001;18375-18383
23. Yu V.C., Naar A.M., Rosenfeld M.G. Transcriptional regulation by the nuclear receptor superfamily. Curr. Opin. Biotechnol. 3(6):1992;597-602
24. Xu L., Glass C.K., Rosenfeld M.G. Coactivator and corepressor complexes in nuclear receptor function. Curr. Opin. Genet. Dev. 9(2):1999;140-147
25. Ribeiro R.C., Kushner P.J., Baxter J.D. The nuclear hormone receptor gene superfamily. Annu. Rev. Med. 46:1995;443-453
26. Chen J.D. Steroid/nuclear receptor coactivators. Vitam Horm. 58:2000;391-448
27. McKenna N.J., Xu J., Nawaz Z., Tsai S.Y., Tsai M.J., O'Malley B.W. Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J. Steroid Biochem. Mol. Biol. 69(1-6):1999;3-12
28. Robinson-Rechavi M., Escriva Garcia H., Laudet V. The nuclear receptor superfamily. J. Cell Sci. 116(Pt 4):2003;585-586
29. Khan O.Y., Nawaz Z. Nuclear hormone receptor co-regulators. Curr. Opin. Drug Discovery Dev. 6(5):2003;692-701
30. Fu M., Wang C., Zhang X., Pestell R. Nuclear receptor modifications and endocrine cell proliferation. J. Steroid Biochem. Mol. Biol. 85(2-5):2003;133-138
31. Fu M., Wang C., Wang J., Zafonte B.T., Lisanti M.P., Pestell R.G. Acetylation in hormone signaling and the cell cycle. Cytokine Growth Factor Rev. 13(3):2002;259-276
32. Gaughan L., Brady M.E., Cook S., Neal D.E., Robson C.N. Tip60 is a co-activator specific for class I nuclear hormone receptors. J. Biol. Chem. 276(50):2001;46841-46848
33. Burris T.P., Nawaz Z., Tsai M.J., O'Malley B.W. A nuclear hormone receptor-associated protein that inhibits transactivation by the thyroid hormone and retinoic acid receptors. Proc. Natl. Acad. Sci. U.S.A. 92(21):1995;9525- 9529
34. Fan S., Ma Y.X., Wang C., Yuan R.Q., Meng Q., Wang J.A., et al. p300 Modulates the BRCA1 inhibition of estrogen receptor activity. Cancer Res. 62(1):2002;141-151
35. Xue Y., Wong J., Moreno G.T., Young M.K., Cote J., Wang W. NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Mol. Cell. 2(6):1998;851-861
36. Zamir I., Zhang J., Lazar M.A. Stoichiometric and steric principles governing repression by nuclear hormone receptors. Genes Dev. 11(7):1997;835-846
37. Aarnisalo P., Palvimo J.J., Janne O.A. CREB-binding protein in androgen receptor-mediated signaling. Proc. Natl. Acad. Sci. U.S.A. 95(5):1998;2122-2127
38. Jenster G., Trapman J., Brinkmann A.O. Nuclear import of the human androgen receptor. Biochem J. 293(Pt. 3):1993;761-768
39. Fu M, Rao M, Wu K, Wang C, Zhang X, Hessien M, Yeung YG, Gioeli D, Weber MJ, Pestell RG. The androgen receptor acetylation site regulates cAMP, AKT but not ERK-induced activity. J. Biol. Chem. 2004;279(28):29436-49.
40. Thomas M., Dadgar N., Aphale A., Harrell J.M., Kunkel R., Pratt W.B., et al. Androgen receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation similar to expanded glutamine tracts. J. Biol. Chem. 279(9):2004;8389-8395
41. Tilley W.D., Buchanan G., Hickey T.E., Bentel J.M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin. Cancer Res. 2(2):1996;277-285
42. Balk S.P. Androgen receptor as a target in androgen-independent prostate cancer. Urology. 60(3 Suppl. 1):2002;132-138. (discussion 138-139)
43. Debes J.D., Sebo T.J., Lohse C.M., Murphy L.M., Haugen de A.L., Tindall D.J. p300 in prostate cancer proliferation and progression. Cancer Res. 63(22):2003;7638-7640
44. Gregory C.W., He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61(11):2001;4315-4319
45. Fujimoto N., Mizokami A., Harada S., Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology. 58(2):2001;289-294
46. Kato S., Tora L., Yamauchi J., Masushige S., Bellard M., Chambon P. A far upstream estrogen response element of the ovalbumin gene contains several half-palindromic 5′-TGACC-3′ motifs acting synergistically. Cell. 68(4):1992;731-742
47. Kato S., Masuhiro Y., Watanabe M., Kobayashi Y., Takeyama K.I., Endoh H., et al. Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells. 5(8):2000;593-601
48. Kraus W.L., Kadonaga J.T. p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev. 12(3):1998;331-342
49. Kraus W.L., Manning E.T., Kadonaga J.T. Biochemical analysis of distinct activation functions in p300 that enhance transcription initiation with chromatin templates. Mol. Cell Biol. 19(12):1999;8123-8135
50. Hanstein B., Eckner R., DiRenzo J., Halachmi S., Liu H., Searcy B., Kurokawa R., Brown M. p300 is a component of an estrogen receptor coactivator complex. Proc. Natl. Acad. Sci. U.S.A. 93(21):1996;11540-11545
51. Fuqua S.A., Wiltschke C., Zhang Q.X., Borg A., Castles C.G., Friedrichs W.E., et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 60(15):2000;4026-4029
52. Kurebayashi J., Otsuki T., Kunisue H., Tanaka K., Yamamoto S., Sonoo H. Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin. Cancer Res. 6(2):2000;512-518
53. Girault I., Lerebours F., Amarir S., Tozlu S., Tubiana-Hulin M., Lidereau R., et al. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin. Cancer Res. 9(4):2003;1259-1266
54. Bautista S., Valles H., Walker R.L., Anzick S., Zeillinger R., Meltzer P., Theillet C. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin. Cancer Res. 4(12):1998;2925-2929
55. Shang Y., Hu X., DiRenzo J., Lazar M.A., Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 103(6):2000;843-852
56. Zwijsen R.M., Wientjens E., Klompmaker R., van der Sman J., Bernards R., Michalides R.J. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 88(3):1997;405-415
57. Zwijsen R.M., Buckle R.S., Hijmans E.M., Loomans C.J., Bernards R. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. 12(22):1998;3488-3498
58. Petre C.E., Wetherill Y.B., Danielsen M., Knudsen K.E. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J. Biol. Chem. 277(3):2002;2207-2215
59. Reutens A.T., Fu M., Wang C., Albanese C., McPhaul M.J., Sun Z., et al. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol. Endocrinol. 15(5):2001;797-811
60. Petre-Draviam C.E., Cook S.L., Burd C.J., Marshall T.W., Wetherill Y.B., Knudsen K.E. Specificity of cyclin D1 for androgen receptor regulation. Cancer Res. 63(16):2003;4903-4913
61. Lee K.C., Li J., Cole P.A., Wong J., Kraus W.L. Transcriptional activation by thyroid hormone receptor-beta involves chromatin remodeling, histone acetylation, and synergistic stimulation by p300 and steroid receptor coactivators. Mol. Endocrinol. 17(5):2003;908-922
62. Hsia S.C., Wang H., Shi Y.B. Involvement of chromatin and histone acetylation in the regulation of HIV-LTR by thyroid hormone receptor. Cell Res. 11(1):2001;8-16
63. Hsia S.C., Shi Y.B. Chromatin disruption and histone acetylation in regulation of the human immunodeficiency virus type 1 long terminal repeat by thyroid hormone receptor. Mol. Cell Biol. 22(12):2002;4043-4052
64. Hsia S.C., Tomita A., Obata K., Paul B., Buchholz D., Shi Y.B. Role of chromatin disruption and histone acetylation in thyroid hormone receptor action: implications in the regulation of HIV-1 LTR. Histol. Histopathol. 18(1):2003;323-331
65. Hamm J.K., el Jack A.K., Pilch P.F., Farmer S.R. Role of PPAR gamma in regulating adipocyte differentiation and insulin-responsive glucose uptake. Ann. NY Acad. Sci. 892:1999;134-145
66. Lee Y., Huang T.S., Yang M.L., Huang L.R., Chen C.H., Lu F.J. Peroxisome proliferation, adipocyte determination and differentiation of C3H10T1/2 fibroblast cells induced by humic acid: induction of PPAR in diverse cells. J. Cell Physiol. 179(2):1999;218-225
67. Chawla A., Schwarz E.J., Dimaculangan D.D., Lazar M.A. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 135(2):1994;798-800
68. Wang C., Fu M., D'Amico M., Albanese C., Zhou J.N., Brownlee M., et al. Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol. Cell Biol. 21(9):2001;3057-3070
69. Jain S., Pulikuri S., Zhu Y., Qi C., Kanwar Y.S., Yeldandi A.V., et al. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am. J. Pathol. 153(2):1998;349-354
70. Zhu Y., Kan L., Qi C., Kanwar Y.S., Yeldandi A.V., Rao M.S., et al. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J. Biol. Chem. 275(18):2000;13510-13516
71. Corton J.C., Anderson S.P., Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. Annu. Rev. Pharmacol. Toxicol. 40:2000;491-518
72. Gelman L., Zhou G., Fajas L., Raspe E., Fruchart J.C., Auwerx J. p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J. Biol. Chem. 274(12):1999;7681-7688
73. Gurnell M., Wentworth J.M., Agostini M., Adams M., Collingwood T.N., Provenzano C., et al. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J. Biol. Chem. 275(8):2000;5754-5759
74. Takashima T., Fujiwara Y., Higuchi K., Arakawa T., Yano Y., Hasuma T., et al. PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int. J. Oncol. 19(3):2001;465-471
75. Jackson L., Wahli W., Michalik L., Watson S.A., Morris T., Anderton K., et al. Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer. Gut. 52(9):2003;1317-1322
76. Nagamine M., Okumura T., Tanno S., Sawamukai M., Motomura W., Takahashi N., et al. PPAR gamma ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer Sci. 94(4):2003;338-343
77. Heaney A.P., Fernando M., Melmed S. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J. Clin. Invest. 111(9):2003;1381-1388
78. Kawa S., Nikaido T., Unno H., Usuda N., Nakayama K., Kiyosawa K. Growth inhibition and differentiation of pancreatic cancer cell lines by PPAR gamma ligand troglitazone. Pancreas. 24(1):2002;1-7
79. Segawa Y., Yoshimura R., Hase T., Nakatani T., Wada S., Kawahito Y., et al. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate. 51(2):2002;108-116
80. Mueller E., Sarraf P., Tontonoz P., Evans R.M., Martin K.J., Zhang M., et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell. 1(3):1998;465-470
81. Sato H., Ishihara S., Kawashima K., Moriyama N., Suetsugu H., Kazumori H., et al. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br. J. Cancer. 83(10):2000;1394-1400
82. Wang C., Pattabiraman N., Zhou J.N., Fu M., Sakamaki T., Albanese C., et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol. Cell Biol. 23(17):2003;6159-6173
83. Wilson V.G., Rangasamy D. Intracellular targeting of proteins by sumoylation. Exp. Cell Res. 271(1):2001;57-65
84. Wilson V.G., Rangasamy D. Viral interaction with the host cell sumoylation system. Virus Res. 81(1-2):2001;17-27
85. Kahyo T., Nishida T., Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Mol Cell. 8(3):2001;713-718
86. Mo Y.Y., Yu Y., Shen Z., Beck W.T. Nucleolar delocalization of human topoisomerase I in response to topotecan correlates with sumoylation of the protein. J. Biol. Chem. 277(4):2002;2958-2964
87. Ueda H., Goto J., Hashida H., Lin X., Oyanagi K., Kawano H., et al. Enhanced SUMOylation in polyglutamine diseases. Biochem. Biophys. Res. Commun. 293(1):2002;307-313
88. Sobko A., Ma H., Firtel R.A. Regulated SUMOylation and ubiquitination of DdMEK1 is required for proper chemotaxis. Dev. Cell. 2(6):2002;745-756
89. Rallabhandi P., Hashimoto K., Mo Y.Y., Beck W.T., Moitra P.K., D'Arpa P. Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin. J. Biol. Chem. 277(42):2002;40020-40026
90. Kim J., Cantwell C.A., Johnson P.F., Pfarr C.M., Williams S.C. Transcriptional activity of CCAAT/enhancer-binding proteins is controlled by a conserved inhibitory domain that is a target for sumoylation. J. Biol. Chem. 277(41):2002;38037-38044
91. Miyauchi Y., Yogosawa S., Honda R., Nishida T., Yasuda H. Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes. J. Biol. Chem. 277(51):2002;50131-50136
92. Kishi A., Nakamura T., Nishio Y., Maegawa H., Kashiwagi A. Sumoylation of Pdx1 is associated with its nuclear localization and insulin gene activation. Am. J. Physiol. Endocrinol. Metab. 284(4):2003;E830-E840
93. Li Y., Wang H., Wang S., Quon D., Liu Y.W., Cordell B. Positive and negative regulation of APP amyloidogenesis by sumoylation. Proc. Natl. Acad. Sci. U.S.A. 100(1):2003;259-264
94. Yamamoto H., Ihara M., Matsuura Y., Kikuchi A. Sumoylation is involved in beta-catenin-dependent activation of Tcf-4. EMBO J. 22(9):2003;2047-2059
95. Lin X., Sun B., Liang M., Liang Y.Y., Gast A., Hildebrand J., Brunicardi F.C., Melchior F., Feng X.H. Opposed regulation of corepressor CtBP by SUMOylation and PDZ binding. Mol. Cell. 11(5):2003;1389-1396
96. Lee P.S., Chang C., Liu D., Derynck R. Sumoylation of Smad4, the common Smad mediator of transforming growth factor-beta family signaling. J. Biol. Chem. 278(30):2003;27853-27863
97. Chauchereau A., Amazit L., Quesne M., Guiochon-Mantel A., Milgrom E. Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J. Biol. Chem. 278(14):2003;12335-12343
98. Gross M, Yang R, Top I, Gasper C, Shuai K. PIASy-mediated repression of the androgen receptor is independent of sumoylation. Oncogene 2004;23(17):3059-66.
99. Le Drean Y., Mincheneau N., Le Goff P., Michel D. Potentiation of glucocorticoid receptor transcriptional activity by sumoylation. Endocrinology. 143(9):2002;3482-3489
100. Nishida T., Yasuda H. PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. J. Biol. Chem. 277(44):2002;41311-41317
101. Sharma M., Li X., Wang Y., Zarnegar M., Huang C.Y., Palvimo J.J., et al. hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. EMBO J. 22(22):2003;6101-6114
102. Poukka H., Karvonen U., Janne O.A., Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. U.S.A. 97(26):2000;14145-14150
103. Ohshima T, Koga H, Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor-gamma is modulated by SUMO-1 modification. J Biol Chem 2004;279(28):29551-7.
104. Lin H.K., Wang L., Hu Y.C., Altuwaijri S., Chang C. Phosphorylation- dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 21(15):2002;4037-4048
105. Leduc A.M., Trent J.O., Wittliff J.L., Bramlett K.S., Briggs S.L., Chirgadze N.Y., et al. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proc. Natl. Acad. Sci. U.S.A. 100(20):2003;11273-11278
106. Rodriguez A.L., Tamrazi A., Collins M.L., Katzenellenbogen J.A. Design, synthesis, and in vitro biological evaluation of small molecule inhibitors of estrogen receptor alpha coactivator binding. J. Med. Chem. 47(3):2004;600-611
107. Zechel C. Synthetic retinoids dissociate coactivator binding from corepressor release. J. Recept. Signal. Transduct. Res. 22(1-4):2002;31-61
108. Hall J.M., Chang C.Y., McDonnell D.P. Development of peptide antagonists that target estrogen receptor beta-coactivator interactions. Mol. Endocrinol. 14(12):2000;2010-2023